/PRNewswire/ Global biotechnology leader CSL (ASX: CSL; USOTC:CSLLY) today celebrated the official opening of the company s new state-of-the-art research.
Hot off the successful deployment of mRNA vaccines for the prevention of COVID-19, three leading drugmakers have moved seasonal flu vaccine candidates built with the technology into early clinical testing. More companies intend to follow their.